Quoin Pharmaceuticals, Ltd. (QNRX)
| Previous Close | 0.5850 |
| Open | 0.5990 |
| Bid | 0.5674 x 100 |
| Ask | 0.6375 x 100 |
| Day's Range | 0.5906 - 0.6120 |
| 52 Week Range | 0.4770 - 6.1800 |
| Volume | |
| Avg. Volume | 2,626,910 |
| Market Cap | 3.005M |
| Beta (5Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6600 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- Zacks Small Cap Research
QNRX: International Sites Participating in QRX003 NS Study, Studying QRX003 for Additional Diseases, in Younger Populations
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT U.S. and International Sites participating in QRX003 NS study, Expanding to study QRX003 for additional indications and in younger patient populations Quoin Pharmaceuticals (NASDAQ:QNRX) provided a business update last week. The company implemented a number of measures during the quarter to move lead asset QRX003 forward. For instance,
GlobeNewswireQuoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and anno
